SCHEMBL5368864

SCHEMBL5368864

OC1CCN1C(c1ccccc1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 13/20 0.47
OPRK1 P41145 12/20 0.47
OPRL1 P41146 12/20 0.47
OPRD1 P41143 11/20 0.47
ALDH1A1 P00352 1/20 0.44
L3MBTL3 Q96JM7 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KCNA3 P22001 1/20 0.42
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
ADRA2A P08913 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CYP2D6 P10635 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
DRD1 P21728 1/20 0.41
ADRA1D P25100 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5744607 0.81 OPRD1 (0.42) OPRM1OPRK1OPRL1OPRD1ALDH1A1
SCHEMBL9792723 0.76 OPRM1 (0.51) OPRM1OPRK1OPRL1OPRD1L3MBTL3
SCHEMBL13163119 0.76 OPRM1 (0.51) OPRM1OPRK1OPRL1OPRD1L3MBTL3
SCHEMBL21787342 0.76 OPRM1 (0.51) OPRM1OPRK1OPRL1OPRD1L3MBTL3
SCHEMBL5685743 0.76 ALDH1A1 (0.47) OPRM1OPRK1OPRL1OPRD1ALDH1A1
SCHEMBL8534618 0.76 OPRM1 (0.46) OPRM1OPRK1OPRL1OPRD1ALDH1A1
SCHEMBL11461609 0.76 OPRM1 (0.55) OPRM1OPRK1OPRL1OPRD1ALDH1A1
SCHEMBL5685739 0.76 ALDH1A1 (0.47) OPRM1OPRK1OPRL1OPRD1ALDH1A1
SCHEMBL5685826 0.76 ALDH1A1 (0.47) OPRM1OPRK1OPRL1OPRD1ALDH1A1
Methane SCHEMBL11728059 0.74 OPRM1 (0.50) OPRM1OPRK1OPRL1OPRD1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186715-B2 Piperazine- and piperidine-derivatives as melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-03-06 US disclosed
EP-1246810-B1 PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS ORTHO MCNEIL PHARM INC (US) 2006-05-17 EP disclosed
CN-1227238-C Piperidinyloxy and pyrrolidinyloxyphenyl oxazolidiones as antibacterials ORTHO MCNEIL PHARM INC (US) 2005-11-16 CN disclosed
EP-1370558-B1 PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-24 EP disclosed
US-20040082590-A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists ELI LILLY AND COMPANY 2004-04-29 US disclosed
EP-1370558-A1 PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-12-17 EP disclosed
CN-1434810-A Piperidyloxy and pyrrolidinophenyl oxazolidinones as antibacterial agents ORTHO MCNEIL PHARM INC (US) 2003-08-06 CN disclosed
US-6518285-B2 4-oxo-5-oxazolidineylmethyl derivatives; antibacterials which are active against numerous multidrug-resistant gram positive organisms ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-02-11 US disclosed
EP-1246810-A1 PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS Ortho-McNeil Pharmaceutical, Inc. (US) 2002-10-09 EP disclosed
US-20020103377-A1 Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-08-01 US disclosed
WO-2002059117-A1 PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed
WO-2001046164-A1 PIPERIDINYLOXY AND PYRROLIDINYLOXYPHENYL OXAZOLIDINONES AS ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-06-28 WO disclosed
US-5258362-A Enzyme inhibitors, amides with oxetane ring ABBOTT LABORATORIES (US) 1993-11-02 US disclosed
WO-1992022313-A1 RENIN INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1992-12-23 WO disclosed
US-5063208-A Cardiovascular disorders, vision defects ABBOTT LABORATORIES (US) 1991-11-05 US disclosed
EP-0416393-A1 Peptidyl difluorodiol renin inhibitors ABBOTT LABORATORIES (US) 1991-03-13 EP disclosed
EP-0410260-A2 Peptidyl aminodiol renin inhibitors ABBOTT LABORATORIES (US) 1991-01-30 EP disclosed
WO-1989010751-A1 FUNCTIONALIZED PEPTIDYL AMINODIOLS AND -TRIOLS ABBOTT LABORATORIES (US) 1989-11-16 WO disclosed
EP-0341602-A2 Renin-inhibiting functionalized peptidyl aminodiols and - triols ABBOTT LABORATORIES (US) 1989-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103377-A1 Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials OXA1L, RPS27L, RPS27 OPRM1 546/4885OPRK1 1070/4885OPRL1 1129/4885
US-20040082590-A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists MC1R, MC4R, MC5R OPRM1 42/4885OPRK1 54/4885OPRL1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.